Search research articles
Contact Us
Filters
Showing results (31-40 of 434) with videos related to
Page
of 44
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
Novel immunotherapies in the treatment of AML: is there hope?
Marion Subklewe, Veit Bücklein, David Sallman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 4, 2021
SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML
Kapil Saxena, Courtney DiNardo, Naval Daver, et al.
Expert Review of Hematology
|
February 25, 2016
Acute myeloid leukemia: advancing clinical trials and promising therapeutics
Naval Daver, Jorge Cortes, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 1, 2020
Harnessing Apoptosis in AML
Kapil Saxena, Courtney DiNardo, Naval Daver, et al.
Expert Review of Hematology
|
August 12, 2017
Immunotherapy based approaches in myelofibrosis
Lucia Masarova, Srdan Verstovsek, Hagop Kantarjian, et al.
Current Opinion in Hematology
|
December 6, 2017
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors
Rita Assi, Hagop Kantarjian, Farhad Ravandi, et al.
Critical Reviews in Oncology/Hematology
|
July 13, 2016
Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Aziz Nazha, Joseph D Khoury, Srdan Verstovsek, et al.
Therapeutic Advances in Hematology
|
February 26, 2019
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Nicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia
|
May 6, 2021
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Naval Daver, Ahmad S Alotaibi, Veit Bücklein, et al.
The Oncologist
|
August 26, 2015
Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications
Aziz Nazha, Joseph D Khoury, Raajit K Rampal, et al.
Page
of 44
Search research articles
Search
Showing results (31-40 of 434) with videos related to
Sort By:
Page
of 44
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
Novel immunotherapies in the treatment of AML: is there hope?
Marion Subklewe, Veit Bücklein, David Sallman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 4, 2021
SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML
Kapil Saxena, Courtney DiNardo, Naval Daver, et al.
Expert Review of Hematology
|
February 25, 2016
Acute myeloid leukemia: advancing clinical trials and promising therapeutics
Naval Daver, Jorge Cortes, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 1, 2020
Harnessing Apoptosis in AML
Kapil Saxena, Courtney DiNardo, Naval Daver, et al.
Expert Review of Hematology
|
August 12, 2017
Immunotherapy based approaches in myelofibrosis
Lucia Masarova, Srdan Verstovsek, Hagop Kantarjian, et al.
Current Opinion in Hematology
|
December 6, 2017
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors
Rita Assi, Hagop Kantarjian, Farhad Ravandi, et al.
Critical Reviews in Oncology/Hematology
|
July 13, 2016
Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Aziz Nazha, Joseph D Khoury, Srdan Verstovsek, et al.
Therapeutic Advances in Hematology
|
February 26, 2019
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Nicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia
|
May 6, 2021
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Naval Daver, Ahmad S Alotaibi, Veit Bücklein, et al.
The Oncologist
|
August 26, 2015
Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications
Aziz Nazha, Joseph D Khoury, Raajit K Rampal, et al.
Page
of 44